VPCnt-101 is the first effective treatment of the severe inflammatory disease initiated by the SCI. This oral formulation contains xanthohumol, a small molecule with an excellent safety profile that inhibits post-SCI severe inflammation resulting in neuroprotection and elimination of the paralyzing swelling.

xanthohumol administered orally crosses the blood brain barrier and reduces numbers of inflammatory cells, macrophages in the SCI lesion. This results in (1) neuroprotection, less damage to the spinal cord by severity of inflammation and in (2) less damage to blood vessels resulting in less leakage that is effectively managed by spinal mechanisms removing excess water resulting in recovery of motor function.

In the spring of 2025, in a small clinical study conducted by prof. W. Dabrowski at the Medical University of Lublin, Poland, nine acute SCI patients were administered orally with a dose of xanthohumol previously optimized in the rat model and then translated to humans. Continuous administration of this dose 3x per day for 10 days resulted in recovery of motor function in all patients. Unprecedented.

Recovery of own breathing allowed for  detachment of external respirator and recovery of movement of arms and legs in patients admitted to the hospital quadriplegic. MRI detected the lack of swelling, edema in the spinal cord of patients treated with xanthohumol. Contrary to that, untreated patients, controls, had edema in the spinal cord and never recovered.

This small clinical study and the studies involving the rat model of SCI are being prepared for publication by Dabrowski, Kwiecien, et al.

The oral formulation of xanthohumol is undergoing regulatory testing program mandated by Health Canada leading to clinical trials mandated by FDA and to market approvals for treatment of disease initiated by the SCI. Subsequently, VPCnt-101 will undergo testing in clinical trials involving patients with acute TBI, concussion and stroke.